Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardio-protective Effect of Cardiomyopeptidin on Myocardial Injury in ICU Patients
NCT06117046Phase 4Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial in Myocardial injury comparing Cardiopeptidin with Placebo (2 arms). Primary endpoint: Major Adverse Cardiac Events at 28 days. Started Mar 2024; status: completed.
02
Drugs
cardiomyopeptidin
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT06117046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06117046.